Targeted antiestrogens to prevent breast cancer

V. Craig Jordan

doi:10.1016/S1043-2760(99)00181-2

Targeted antiestrogens to prevent breast cancer

V. Craig Jordan

Research output: Contribution to journal › Review article › peer-review

36 Scopus citations

Abstract

Tamoxifen, the first selective estrogen receptor modulator (SERM), has provided invaluable laboratory and clinical evidence that such drugs can reduce the risk of breast cancer and increase bone density. Raloxifene is available for the prevention of osteoporosis, and preliminary studies show a decrease in breast cancer risk. On the basis of current information about the pharmacology of SERMs, a large breast cancer prevention trial called study of tamoxifen and raloxifene (STAR) has started in the USA. Results should be available in the next seven years.

Original language	English (US)
Pages (from-to)	312-317
Number of pages	6
Journal	Trends in Endocrinology and Metabolism
Volume	10
Issue number	8
DOIs	https://doi.org/10.1016/S1043-2760(99)00181-2
State	Published - 1999
Externally published	Yes

ASJC Scopus subject areas

Endocrinology, Diabetes and Metabolism
Endocrinology

Access to Document

10.1016/S1043-2760(99)00181-2

Cite this

@article{74fb145a7e0a47549476bb9a623ffdc9,

title = "Targeted antiestrogens to prevent breast cancer",

abstract = "Tamoxifen, the first selective estrogen receptor modulator (SERM), has provided invaluable laboratory and clinical evidence that such drugs can reduce the risk of breast cancer and increase bone density. Raloxifene is available for the prevention of osteoporosis, and preliminary studies show a decrease in breast cancer risk. On the basis of current information about the pharmacology of SERMs, a large breast cancer prevention trial called study of tamoxifen and raloxifene (STAR) has started in the USA. Results should be available in the next seven years.",

author = "Jordan, {V. Craig}",

year = "1999",

doi = "10.1016/S1043-2760(99)00181-2",

language = "English (US)",

volume = "10",

pages = "312--317",

journal = "Trends in Endocrinology and Metabolism",

issn = "1043-2760",

publisher = "Elsevier Inc.",

number = "8",

}

TY - JOUR

T1 - Targeted antiestrogens to prevent breast cancer

AU - Jordan, V. Craig

PY - 1999

Y1 - 1999

N2 - Tamoxifen, the first selective estrogen receptor modulator (SERM), has provided invaluable laboratory and clinical evidence that such drugs can reduce the risk of breast cancer and increase bone density. Raloxifene is available for the prevention of osteoporosis, and preliminary studies show a decrease in breast cancer risk. On the basis of current information about the pharmacology of SERMs, a large breast cancer prevention trial called study of tamoxifen and raloxifene (STAR) has started in the USA. Results should be available in the next seven years.

AB - Tamoxifen, the first selective estrogen receptor modulator (SERM), has provided invaluable laboratory and clinical evidence that such drugs can reduce the risk of breast cancer and increase bone density. Raloxifene is available for the prevention of osteoporosis, and preliminary studies show a decrease in breast cancer risk. On the basis of current information about the pharmacology of SERMs, a large breast cancer prevention trial called study of tamoxifen and raloxifene (STAR) has started in the USA. Results should be available in the next seven years.

UR - http://www.scopus.com/inward/record.url?scp=0001122847&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0001122847&partnerID=8YFLogxK

U2 - 10.1016/S1043-2760(99)00181-2

DO - 10.1016/S1043-2760(99)00181-2

M3 - Review article

C2 - 10481161

AN - SCOPUS:0001122847

SN - 1043-2760

VL - 10

SP - 312

EP - 317

JO - Trends in Endocrinology and Metabolism

JF - Trends in Endocrinology and Metabolism

IS - 8

ER -

Targeted antiestrogens to prevent breast cancer

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this